http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2008016524-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
| filingDate | 2007-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c154a5890245cbb7077e196fb9468b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4445ead7cc643ec15b53439462913dc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b1bdc64cda39587c481f4ee2fcf4fc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0139190df4a3250cf1c6aac6be1860bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_382f20c405eb2f93a7003218e58590b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_696d5e77608af89f5e484e6efd45db35 |
| publicationDate | 2009-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2008016524-A |
| titleOfInvention | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE. |
| abstract | The genetic polymorphism of LRRK2 (repetitive leucine-rich kinase 2) -T1602S is significantly associated with the conversion of moderate cognitive impairment (MCI) to Alzheimer's disease (AD), in patients with the TT genotype who are older risk of progressing to Alzheimer's disease. The LRRK2-T2352 also showed a tendency to conversion to Alzheimer's disease, in patients with the CC genotype who tend to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, an LRRK2-T1602S and an LRRK2-T2352 showed a greater association with the conversion rate of moderate cognitive impairment to Alzheimer's disease. In another study in patients with Alzheimer's disease treated with placebo, LRRK2-T1602S and LRRK2-T2352 showed the same association trend. Patients with Alzheimer's disease with the TT genotype of LRRK2-T1602S or with the CC genotype of LRRK2-T2352 tended to decrease cognitive functioning more rapidly for 6 months, especially in the presence of a BuChE-K variant. The association between the two polymorphisms of LRRK2 and the progress of Alzheimer's disease showed that LRRK2 can play a role in the pathogenesis of Alzheimer's disease, especially in the progression of the disease, and that LRRK2 polymorphisms can be used as Biological markers of this progress. |
| priorityDate | 2006-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.